Showing 341-350 of 6808 results for "".
SCALE 2024: Dr. Hilary Baldwin on Benzyl Peroxide Best Practices
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-hilary-baldwin-benzyl-peroxide-best-practices/26375/Hilary E. Baldwin, MD, provides and update on the recent issues surrounding benzyl peroxide, including a recommendation to dispose of any expired benzyl peroxide products and a discussion of proper storage, at Music City SCALE.AbbVie's Skyrizi Approved, Brooke Shields Endorses SculpSure
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-abbvies-skyrizi-approved-brooke-shi/19607/Skyrizi, an interleukin-23 inhibitor from AbbVie, is FDA approved for the treatment of moderate to severe plaque psoriasis in adults. Brooke Shields is the face of the new “Be strong. Be sexy. Be confident” campaign for SculpSure, from Hologic’s Cynosure. The Noah Worcester Dermatological Society anNoah Worcester 2024: Dr. Bridges on Practice Management
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-bridges-practice-management/24580/Alina Bridges, DO, FAAD, summarizes her lecture on practice management and coding at the 2024 Noah Worcester Dermatological Society meeting.Clinical Conversations: Risks vs Benefits of JAK Inhibitors
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-risks-vs-benefits-of-jak-inhibitors/20108/Clinical data for JAK inhibitors show clear benefits for many patients. But these drugs are associated with certain risks and class warnings. Matt Zirwas, MD and Adelaide Hebert, MD describe how they weigh risks, educate patients, and optimize long-term management.DERM2020 Exhibitor Reaction: Brett Fair, EPI Health
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-exhibitor-reaction-brett-fair-epi-health/19847/Brett Fair of EPI Health, a DERM2020 exhibitor, tells us what he thinks of the new virtual meeting world and how DEF is dominating it for dermatology!DERM2020 Content Recap: Brad Glick, DO, MPH
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-content-recap-brad-glick-do/19840/DERM2020 Faculty Brad Glick, DO, MPH shares his thoughts on DERM2020 and some of the presentations around COVID.Almirall/Allergan, LEO/Bayer Deals
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-almirall-allergan-leo-bayer-deals/18240/Leo Pharma has agreed to acquire Bayer's global prescription dermatology unit, and Almirall will acquire Allergan's US portfolio of medical dermatology drugs. When it comes to patient engagement, aesthetic practices often have the right mindset, but they may lack the skills or time necessary to execBiosimilar Recommended; Saunders to Head New Pfizer/Allergan Organization
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-biosimilar-recommended-saunders-to-head-new-pfizer-allergan-organization/18825/An FDA committee has recommended Pfizer's Inflectra, biosimilar to infliximab, developed by Celltrion. Sunbelt Melanoma Trial finds no benefit for IFN in Phase III melanoma. Pfizer/Allergan provides details on structure of new organization and announces leadership, including President and COO BrentDermwireTV: Counterfeit Botox Cases Widen; New HS Treatment Approved in Europe
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-counterfeit-botox-cases-widen-new-hs-treatment-approved-europe/24419/In this episode of DermwireTV, the use of counterfeit Botox continues to widen; a first-of-its-kind drug is approved in Europe for hidradenitis suppurativa; and the PA Perspective series provides tips for training and onboarding in a new practice.Treatment Breaks for Super Responders: An Update from the GUIDE Study of Guselkumab in Psoriasis
https://practicaldermatology.com/topics/psoriasis/treatment-breaks-for-super-responders-an-update-from-the-guide-study-of-guselkumab-in-psoriasis/20222/Knut Schäkel, MD, a dermatologist at Heidelberg University Hospital in Germany, shares data on the withdrawal stage of the GUIDE study of guselkumab (Tremfya) in moderate-to-severe plaque psoriasis from his talk at the 2023 European Academy of Dermatology and Venereology meeting in Berlin.